Home
About
Research
Blog
Development
Contact
08
2024-08
For solid tumors, the world's first CD99 CAR-T cell therapy product is approved by CDE clinical.
2024-08-08
The kick-off meeting of the BRD-01 phase II clinical trial of Porida biological cell therapy drug was successfully held.
Good news! Polida Biology Selected in 2023 "Science and Technology China" New Enterprise List
[Information] | Hubei Radio and Television: Ten Years of Grinding a Sword CAR-T Anticancer Drugs Produced in Hubei to Be Listed
31
2024-01
Porita Bio's First Cell Therapy Drug BRD-01 Recognized by FDA Orphan Drug Qualification
2024-01-31
01
2023-12
Porida Biologics Statement on FDA's Investigation into CAR-T Cell Therapy May Trigger T-Cell Secondary Tumors
Recently, the company was concerned about the U.S. FDA's announcement on November 28, 2023, on individual reports of T-cell tumors in patients receiving targeted BCMA or CD19 autologous CAR-T cell immunotherapy. The FDA said, "While the overall benefits of the approved uses of these products continue to exceed their potential risks, the FDA is evaluating the need for regulatory action1."
2023-12-01
04
2023-07
Porida probationary party member to become a full member and accept the probationary party member conference
On the morning of June 30, 2023, Porida held the oath of joining the party for new party members and the ceremony for old party members to review the oath of joining the party. All party members solemnly swore in the face of the bright red party flag and expressed their infinite respect and loyalty to the party with a clank oath. Solemn promise and firm determination, encourage oneself to actively practice the oath with practical actions, strive for the first place with a vigorous spirit, and firm belief to follow the party forever.
2023-07-04
03
2023-03
Industry Information | CDE Releases Technical Guidelines for Pharmaceutical Research and Evaluation of Oncolytic Virus Products (Trial)
2023-03-03
CAR-T major good! National Institute for Health and Clinical Excellence (NICE) approves NHS regular use of CAR-T for diffuse large B- cell lymphoma
Quick questions, quick answers! This article takes you to read CAR-T cell therapy.
In recent years, with the continuous progress of cell therapy technology, the word CAR-T has begun to appear frequently in the public eye, and the news of the 1.2 million of an anti-cancer drug is still fresh in the memory of many friends. For ordinary cancer patients and families, the launch of CAR-T products is both gratifying and worrying. On the one hand, it is the hope of survival, and on the other hand, it is the "sky-high price" that countless people cannot afford 』.